Resources from the same session
27O - First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target
Presenter: Timothy Yap
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
46O - Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies
Presenter: Iwona Lugowska
Session: Proffered Paper session
Resources:
Abstract
Invited Discussant
Presenter: Stefan Symeonides
Session: Proffered Paper session
Resources:
Slides
Webcast
109O - Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors
Presenter: Sophie Postel-Vinay
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
1O - Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
Presenter: Timothy Yap
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: Lillian Siu
Session: Proffered Paper session
Resources:
Webcast